ERBB2 and gastric cancer: HER2 gene amplifications and mutations are most prevalent in GBC and eCCA (10–15%), and are less common in iCCA.25,56 Prognosis for HER2 aberrations are unknown for BTCs, but are well known to have aggressive phenotypes in breast and gastric cancers.